Program
Pregabalin
Also written as “pregabalin”, “pregabalin (Lyrica)” and “Pregabalin ER”.
Its studies are mostly in Neuralgia · Fibromyalgia · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 18 companies.
Drug pagePregabalin: every studyMany companies study it; this page follows only the 142 they lead. All 390 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 940 open or running | phase 4since Aug 31, 2005 | Aug 30, 2005 | none ahead |
| Pfizerits history only | 180 open or running | phase 4since Apr 16, 2012 | Aug 30, 2005 | none ahead |
| Yuhan | 80 open or running | phase 4since Apr 13, 2021 | Aug 17, 2011 | none ahead |
| GL Pharm Techits history only | 40 open or running | phase 1since Jul 4, 2012 | Jul 4, 2012 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 30 open or running | phase 3since Apr 4, 2022 | Apr 4, 2022 | none ahead |
| Merckits history only | 20 open or running | phase 1since Dec 7, 2007 | Dec 7, 2007 | none ahead |
| Nevakarits history only | 20 open or running | phase 2since Jul 27, 2020 | Jan 29, 2020 | none ahead |
| Analgesic Solutionsits history only | 10 open or running | phase 4since Dec 13, 2012 | Dec 13, 2012 | none ahead |
| Depomedits history only | 10 open or running | phase 4since Jun 5, 2017 | Jun 5, 2017 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Sep 4, 2014 | Sep 4, 2014 | none ahead |
| Egymedicalpediaits history only | 10 open or running | early phase 1since Apr 8, 2023 | Apr 8, 2023 | none ahead |
| Hypera Pharmaits history only | 11 open or running | phase 3since Jun 18, 2026 | Jun 18, 2026 | Jun 1, 2027phase 3 · NCT07712913 |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 3since Jul 8, 2015 | Jul 8, 2015 | none ahead |
| KRKAits history only | 10 open or running | phase 4since Jan 24, 2020 | Jan 24, 2020 | none ahead |
| Latigo Biotherapeuticsits history only | 10 open or running | early phase 1since Sep 13, 2024 | Sep 13, 2024 | none ahead |
| Unimed Pharmaceuticalsits history only | 10 open or running | phase 1since Mar 3, 2013 | Mar 3, 2013 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 4since Oct 8, 2018 | Oct 8, 2018 | none ahead |
| Yungjin Pharm.its history only | 10 open or running | phase 1since Aug 22, 2017 | Aug 22, 2017 | none ahead |
Also a collaborator on its studies: Nevakar Injectables, Boehringer Ingelheim and Astellas Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Yuhan only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 17, 2011First study: phase 1 study in HealthyFirst studyNCT01420913 · 28 enrolled · Korea, Republic of
- Feb 15, 2016Phase 1 study in Peripheral Neuropathy PainNCT02783638 · 64 enrolled · Korea, Republic of
- May 23, 2016Phase 1 study in Peripheral Nueropathy PainNCT02783183 · 32 enrolled
- Dec 1, 2016Phase 3 study in Peripheral Neuropathic PainNCT02985216 · 371 enrolled · Korea, Republic of
- May 24, 2017Phase 1 study in Peripheral Neuropathic PainNCT03191136 · 24 enrolled · Korea, Republic of
- Jun 9, 2019Named pregabalinINNProposed as its International Nonproprietary Name in WHO's List 121
- Apr 13, 2021Phase 4 study in Diabetic Peripheral NeuropathyNCT04846673 · 151 enrolled · Korea, Republic of
- Jul 27, 2021Phase 1 study in Healthy VolunteerNCT05012436 · 16 enrolled · Korea, Republic of
- Nov 14, 2022Phase 4 study in NeuralgiaNCT05624853 · 130 enrolled · Korea, Republic of
TargetBeta
“Voltage-gated calcium channel modulator”ChEMBL 37, by rule
Other programs on the same 26 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Gabapentinrule | Viatris | phase 4 | 49 |
Studies
All 8 Yuhan leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05624853Neuralgia · Korea, Republic of | 4 | Completed | Dec 20, 2022 | 130 |
| NCT05012436Healthy Volunteer · Korea, Republic of | 1 | Completed | May 10, 2022 | 16 |
| NCT04846673Diabetic Peripheral Neuropathy · Korea, Republic of | 4 | Completed | Nov 30, 2022 | 151 |
| NCT03191136Peripheral Neuropathic Pain · Korea, Republic of | 1 | Completed | Jun 27, 2017 | 24 |
| NCT02985216Peripheral Neuropathic Pain · Korea, Republic of | 3 | Completed | Apr 27, 2018 | 371 |
| NCT02783183Peripheral Nueropathy Pain | 1 | Completed | Aug 2016 | 32 |
| NCT02783638Peripheral Neuropathy Pain · Korea, Republic of | 1 | Completed | Apr 2016 | 64 |
| NCT01420913Healthy · Korea, Republic of | 1 | Completed | Aug 2011 | 28 |
How it is read
Names in the registry
- “Pregabalin”, 80 entries
- “pregabalin”, 43 entries
- “pregabalin (Lyrica)”, 7 entries
- “Pregabalin ER”, 6 entries
- “Pregabalin 150mg”, 5 entries
Codes read as this program: YHD1119.
Conditions, from the studies’ own filings
- Neuralgia, 18 studies
- Fibromyalgia, 16 studies
- Diabetic Neuropathies, 14 studies
- Epilepsies, Partial, 12 studies
- Neuralgia, Postherpetic, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.